Athira Pharma - Alzheimer’s Disease Study
The LIFT-AD Trial is evaluating the safety and effectiveness of an investigational medication for people with mild to moderate Alzheimer’s disease.
Axsome Therapeutics - Alzheimer’s Disease Agitation Study
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion.
J&J - Alzheimer’s Disease Agitation Study
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.
